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Diabetic nephropathy (DN) is a leading cause of end-
stage renal disease (ESRD) in developed countries, as 
type 2 diabetes mellitus has already reached epidemic 
proportions by the beginning of this millennium.1 
Worldwide, DN is the primary diagnosis in 25 to 50% 
of people starting renal replacement therapy for ESRD. 
In the United States, 44% of all new patients starting 
dialysis in 2009 had underlying DN. In Australia, new 
type 2 diabetes patients starting dialysis increased 
5-fold between 1993 and 2007.2 In Japan, there was 
a 7-fold increase in this rate (from 6% in 1983 to the 
current figure of 40%).3 In Hong Kong, the situation is 
no different. The incidence soared from 25% in 1996 to 
46% in 2009, according to Renal Registry data from the 
Central Renal Committee of the Hong Kong Hospital 
Authority.4 Thus in this decade, a major proportion 
of the predicted US$1.1 trillion medical costs of 
providing dialysis worldwide will stem from a single 
disease entity—DN.5
 The global and growing threat of DN due to type 
2 diabetes has long caught the attention of the renal 
community. The International Society of Nephrology 
(ISN, http://www.isn-online.org/isn/society/about/index. 
html)—founded in 1960 with the mission to pursue the 
worldwide advancement of education, science and patient 
care in nephrology—launched the annual World Kidney 
Day (WKD) initiative (http://www.worldkidneyday.org) 
in collaboration with the International Federation of 
Kidney Foundations in 2006. Its objective was to raise 
awareness of the importance of our kidneys to our 
overall health and to reduce the frequency and impact 
of kidney disease and its associated health problems 
worldwide. The 2010 WKD, held on 11 March in 
numerous countries, focused on DN with the slogan 
“Protect your kidneys, Control diabetes”. In Hong 
Kong, this campaign took place on 14 March, and for 
the first time, the Hong Kong Society of Nephrology 
(HKSN) hosted a WKD online Chinese version (http://
wkd.hksn.org/zh_tw/) to increase public awareness 
of diabetic kidney disease within the Chinese 
community. Why have we nephrologists allowed DN 
to grow to such a threatening magnitude over the past 
2 decades? There are a number of astounding reasons. 
 First, there is the relentless increase in the 
prevalence of type 2 diabetes as a result of the 
metabolic syndrome. Despite an emphasis on the 
need for lifestyle changes—such as weight loss, 
diet control, and increased physical exercise—the 
obesity and diabetes epidemic continues to escalate. 
Lamentably, the number of persons with diabetes, 
currently estimated at 150 million, is predicted to 
double by 2025. This epidemic is chiefly of type 2 
diabetes. Moreover, the risk of diabetes increases 
with age, which is particularly worrisome given the 
increasingly ageing population worldwide. 
 Second, the risk factors and pathophysiology of 
DN are not entirely understood. This is reflected by 
the observation that modern diabetes management 
including avid blockade of the renin-angiotensin-
aldosterone system, and stringent control of 
glycaemia, blood pressure, and lipid levels, have 
only achieved limited success in preventing DN 
and retarding its progression to ESRD. For example, 
although DN is traditionally viewed as a primarily 
glomerular disease, emerging evidence indicates 
that tubular activation and injury plays an important 
role in its pathogenesis and progression.6 Reducing 
sugars may react non-enzymatically with amino 
groups in proteins or lipids, resulting in oxidative and 
non-oxidative molecular rearrangements termed the 
Maillard reactions. In this context, the formation of 
stable covalent adducts known as advanced glycation 
end-products (AGEs) appear to be important.7 In 
humans, irreversible advanced glycation is a part of 
the ageing process, which is markedly accelerated 
in diabetes due to hyperglycaemia. Indeed, both 
high glucose and AGEs appear to induce tubular 
inflammation and fibrosis that are intermediate 
processes ultimately leading to loss of renal 
function.8,9 Apart from factors intrinsic to the diabetic 
status, genetic predisposition also plays a critical role 
in multiple ethnic groups.10 Among type 2 diabetics in 
Hong Kong Chinese, for instance, a variant located in 
the acetyl-coenzyme A carboxylase beta gene (ACACB) 
is linked to an increased risk for DN.11
 In terms of renoprotective strategies in 
patients with DN, there is a long way to go. Clearly, 
use of an angiotensin-converting enzyme inhibitor 
or angiotensin II receptor blocker is now standard 
therapy for patients with DN. These agents reduce 
the progression from normoalbuminuria to micro- 
albuminuria,12 from microalbuminuria to macro-
albuminuria,13 and slow the progression to ESRD.14 
Antagonising aldosterone action15 and resorting to 
the direct renin inhibitor16 have shown some promise 
in recent clinical trials.17 However, the use of all these 
agents is often hampered by the development of 
hyperkalaemia, particularly in patients with advanced 
disease and those with renovascular disease (a not-an-
uncommon vasculopathy in diabetes). Although the 
glitazones or the peroxisome proliferator-activated 
receptor (PPAR)-γ agonists may have renoprotective 
effects in animals,18 there are mounting concerns 
that rosiglitazone (Avandia; GlaxoSmithKline, Herts, 
UK) causes fluid retention. A recent re-appraisal of its 
clinical utility by the RECORD investigators19 confirmed 
that the addition of rosiglitazone to glucose-lowering 
therapy in type 2 diabetics increased the risk of heart 
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failure and certain fractures, mainly in women. More 
alarmingly, two further reports20,21 encompassing over 
260 000 patients associated rosiglitazone use with an 
increased risk of myocardial infarction, heart failure, 
stroke, or death. It becomes clear at present that it may 
be unethical to prescribe Avandia or continue clinical 
trials using Avandia, particularly in patients at risk of 
cardiovascular disease. Therefore, the quest for a safe 
and effective protocol or agent to control DN must 
continue.
 Where do we go from here? At the primary 
care level, via education, drugs and diet, we need 
to adequately control all the known reversible risk 
factors, including: blood sugar, blood pressure, 
lipid levels, and body weight. We must also ensure 
smoking cessation, compliance/concordance with 
drug treatment, and avoidance of nephrotoxins (non-
steroidal anti-inflammatory drugs, contrast media, 
unknown herbal medicines, dietary supplements, 
and over-the-counter drugs). Renin-angiotensin-
aldosterone system blockade needs to be administered 
where appropriate. Complication screening protocols 
including those directed at early diabetic kidney 
disease need to be adhered to. We must also come to 
terms with the reality that, with our limited knowledge 
and treatment armamentarium, in some patients 
renal progression will be inevitable and eventually 
require referral for specialist care. Finally, we must 
be alert to recognising non-diabetic renal disease 
among diabetics, and manage their renal disorder 
accordingly. At the tertiary care level, basic research 
and clinical trials must search for a new understanding 
and novel therapies (agents to reduce renal fibrosis or 
blockade of AGE formation and downstream signalling 
pathways). The problem of DN is global and growing, 
and yet the challenge is undoubtedly local and entails 
health care provision from primary to tertiary levels. 
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